Effects of Nonsteroidal Anti-Inflammatory Drugs in Recurrence of Spondyloarthritis Patients After Remission

Effects of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Recurrence of Spondyloarthritis (SPA) Patients After Remission：A Multicenter, Randomized, Controlled Study

The multicenter, randomized controlled trial is to investigate and evaluate the effect of NSAIDs therapy on recurrence in patients with axial spondyloarthritis;

Study Overview

• Status: Recruiting
• Conditions: Axial Spondyloarthritis
• Intervention / Treatment: Drug: To withdraw NSAIDs therapy; Drug: To continue NSAIDs therapy

Detailed Description

To investigate the recurrence rate in remission patients who withdraw NSAIDs therapy in axial spondyloarthritis;

• Study Type: Interventional
• Enrollment (Anticipated): 140
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Shi Guixiu, PhD; Phone Number: 86-0592-13600932661; Email: Gshi@xmu.edu.cn
• Study Contact Backup: Name: Zheng Qing, PhD; Phone Number: 86-0591-18650383162; Email: drmichaelzheng@qq.com

Study Locations

• China
  • Fujian
    • Xiamen, Fujian, China, 361003
      • Recruiting
      • The First Affiliated Hospital of Xiamen University
      • Contact: Shi Guixiu, PhD; Phone Number: 13600932661; Email: Gshi@xmu.edu.cn
      • Contact: Zheng Qing, PhD; Phone Number: 18650383162; Email: drmichaelzheng@qq.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Capable of giving informed consent and complying with the examination program of the protocol;
• Participants with axial SpA fulfilling the Assessment of Spondyloarthritis international Society 2009 (ASAS) axial SpA classification criteria;
• Participants must fulfill the criteria of maintaining remission of aSpA, defined as ASDAS<1.3；
• Participants must fulfill the criteria of remission of aSpA defined as ASDAS<1.3，then continuous to evaluate every four weeks for three times and ASDAS<1.3 each time.
• Laboratory results must fulfill following requirements: Hb≥85g/L；3.5×109/L≤WBC Count ≤10×109/L；Platelet count ≥ Normal lower limit; Liver function (ALT、TBIL) ≤Twofold of normal upper limit; Renal function (SCr) ≤Normal upper limit;
• The pregnancy test must be negative for women of childbearing age; Efficient contraception must be taken for both male and female participants during the trial period and within three months after the end of the trial.

Exclusion Criteria:

• Participants who previously have experienced allergic reactions to NSAIDs or sulfa-drugs;
• Participants who are intolerant of NSAIDs;
• Participants who are in active axSpA episodes;
• Participants with previous or currant ulcers and/or gastrointestinal conditions or bleeding in three months
• Participants who were in acute infection or acute attack of chronic infection during screening period;
• At the time of screening, participants who were in the acute stage of acute infection or chronic infection, and if the acute infection had improved, they could be re-screened.
• Participants who suffer from invasive fungal infections (e.g. histoplasma, coccidiosis's, candida, aspergillus, blastomyces, pneumocystis, etc.) within the first 6 months of screening; Or opportunistic bacterial infections (e.g. bacterial, viral or other infections, including Legionella and Listeria);
• Participants with other autoimmune diseases which are expected to influence the evaluation of experimental medications, such as inflammatory enteritis, psoriasis, uveitis, etc.
• Participants with previous or currant congestive heart failure, coronary heart disease, serious arrhythmia;
• Participants with severe, progressive, uncontrolled vital organ and systematic disorders, and other conditions that are considered inappropriate to participate in this trial;
• Participants with circumstances that may affect the compliance (e.g. prolonged travel or leave, planned relocation, mental illness, lack of motivation to participate, etc.).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Non- NSAIDS group; To withdraw NSAIDS therapy	Drug: To withdraw NSAIDs therapy; NSAIDs therapy will be withdrew after washout period.; Other Names: Non-NSAIDs; Break-off (on-demand) NSAID therapy; Break-off NSAID use (on-demand) group
Active Comparator: NSAIDS group; To continue NSAIDS therapy	Drug: To continue NSAIDs therapy; NSAIDs therapy will be continued.; Other Names: NSAIDs; Regular (continuous) NSAID therapy; Regular (continuous) group

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of participants with Ankylosing Spondylitis Disease Activity Score (ASDAS) active disease	ASDAS active disease is defined as ΔASDAS-CRP≥0.9. The ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation.	From Week 0 (baseline) to Week24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Patient global assessment of disease activity	Participant rated instrument to measure participants' global assessment of disease activity on a 10 cm visual analogue scale, ranging from no activity to highest possible activity.	From Week 0 (baseline) to Week24
Change in total Back Pain	Participants assessed the total back pain they had in the previous 1 week on a scale from 0 (no pain) to 10 (most severe pain).	From Week 0 (baseline) to Week24
Change in Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)	A numeric rating scale was used, for questions 1-5 (Fatigue, Spinal Pain, Joint pain or Swelling, Discomfort and Morning stiffness severity respectively) on a scale from 0 (none) to 10 (very severe). Question 6 (morning stiffness duration) was recorded on a scale of 0 (0 or more hours) to 10 (2 hours). To give the five major Ankylosing Spondylitis (AS) symptoms equal weighting, the average of the two scores relating to morning stiffness was taken. This averaged morning stiffness score was then summed with the remaining 4 questions, resulting in a composite score on a scale of 0-50, which was then divided by 5 to give the final BASDAI score on a scale of 0-10.	From Week 0 (baseline) to Week24
Change in Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)	The BASFI is a participant's self-assessment represented as a mean (VAS; 0 to 10) of 10 questions, 8 of which relate to the participant's functional anatomy and 2 of which relate to a participant's ability to cope with everyday life. An increase along the scale indicates a worsening condition.	From Week 0 (baseline) to Week24
Change in Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)	BASMI is an objective measure of spinal mobility. The BASMI score is composed of 5 measures: cervical rotation, intermalleolar distance, modified Schober's test, lateral flexion and tragus to wall distance. Each measure was scored 0-2 (0=normal mobility, 2=severe reduction) to give a final score ranging 0 to 10.	From Week 0 (baseline) to Week24
Change in Short Form-36 Physical Component Summary (SF-36 PCS)	The change from Baseline in Short Form-36 Physical Component Summary (SF-36 PCS)	From Week 0 (baseline) to Week24
Change in European Quality of Life-5 Dimensions (EQ-5D) Questionnaire	The EQ-5D is an international, standardized, generic instrument for describing and valuing health status.In description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS).Visual analogue scale is the second part of the questionnaire, asking to mark health status on the day of the interview on a 20 cm vertical scale with end points of 0 and 100. There are notes at the both ends of the scale that the bottom rate (0) corresponds to " the worst health you can imagine", and the highest rate (100) corresponds to "the best health you can imagine".	From Week 0 (baseline) to Week24
Change in Chest Expansion	Chest expansion, measured in cm, is defined as the difference in thoracic circumference during full expiration versus full inspiration, measured at the fourth intercostal space (nipple line). Chest expansion was measured for both maximum and minimum inhalation and the data presented below combined both the values.	From Week 0 (baseline) to Week24
Change in Maastricht Ankylosing Spondylitis Enthesitis Index (MASES)	The MASES evaluation will be conducted at the designated study visits to assess the presence or absence of enthesitis at 13 different sites, noting the subjects' responses.	From Week 0 (baseline) to Week24
Change in Number of swelling and tendons affected by enthesitis	An assessment of 44 swelling joints and 46 tendons joints will be done by physical examination at the designated study visits. Joint swelling will be classified as present (1), absent (0), replaced (9), or no assessment (NA).	From Week 0 (baseline) to Week24
Change in Blood samples: C-reactive protein (CRP) and Erythrocyte sedimentation rate(ESR)	General and specific markers of inflammation. ESR will be evaluated at the site and expressed in mm/hg (1st hour).	From Week 0 (baseline) to Week24
Observation of relapse time after withdrawal of NSAIDs in remission patients	ASDAS active disease is defined as ΔASDAS-CRP≥0.9	From Week 0 (baseline) to Week24
The difference of flare rate between different treatment groups	ASDAS active disease is defined as ΔASDAS-CRP≥0.9	Week12 and Week24
The difference of flare rate between in patients with different sacroiliac joint grades on X-ray among different groups.	To grade radiographic sacroiliitis according to the New York criteria: grade0 normal; grade1 suspicious; grade2 minimal sacroiliitis; grade3 moderate sacroiliitis; grade4 ankylosis.	Week12 and Week24
The difference of osteophyte formation between different groups on Modified Stoke ankylosing spondylitis spine score (mSASSS).	mSASSS focuses on the anterior vertebral body angles from the lower T12 endplate to the upper S1 endplate on a lateral radiograph. Each angle is scored 0 (normal), 1 (shiny corner sign, squaring, or sclerosis), 2 (enthesophyte), or 3 (bridging), so that the total score can range from 0 to 72.	Week0 and Week24
Comparison of BASFI and BASMI scores between different groups	The BASFI is a participant's self-assessment represented as a mean (VAS; 0 to 10) of 10 questions, 8 of which relate to the participant's functional anatomy and 2 of which relate to a participant's ability to cope with everyday life. An increase along the scale indicates a worsening condition. BASMI is an objective measure of spinal mobility. The BASMI score is composed of 5 measures: cervical rotation, intermalleolar distance, modified Schober's test, lateral flexion and tragus to wall distance. Each measure was scored 0-2 (0=normal mobility, 2=severe reduction) to give a final score ranging 0 to 10.	Week12 and Week24
Differences in MRI scores among different groups by SPARCC SSS method.	The SPARCC SSS method was developed based on semicoronal T1WSE sequences of the sacroiliac joints (SIJ). The transitional slice is identified by scrolling from anterior to posterior through the SIJ and viewing DICOM images depicting semicoronal slices through the joint. Scoring ranges are fat metaplasia (0-40), erosion (0-40), backfill (0-20), and ankylosis (0-20).	weeks-16, week 0, week 12 and week 24
The difference of flare rate in patients with different MRI scores of sacroiliac joint.	MRI scores are measured by SPARCC SSS method.	Week0 and Week24

Collaborators and Investigators

• Sponsor: The First Affiliated Hospital of Xiamen University
• Collaborators: First Affiliated Hospital of Fujian Medical University; Fujian Medical University Union Hospital; Peking University Shenzhen Hospital; Zhangzhou Affiliated Hospital of Fujian Medical University; Quanzhou Orthopedic-traumatological Hospital of Fujian Traditional Chinese Medicine University
• Investigators: Study Director: Shi Guixiu, PhD, The First Affiliated Hospital of Xiamen University

Publications and helpful links

General Publications

• Zheng Q, Liu W, Huang Y, Gao Z, Wu Y, Wang X, Cai M, He Y, Chen S, Wang B, Liu L, Chen S, Huang H, Zheng L, Kang R, Zeng X, Chen J, Chen H, Chen J, Li Z, Shi G. Predictive Value of Active Sacroiliitis in MRI for Flare Among Chinese Patients with Axial Spondyloarthritis in Remission. Rheumatol Ther. 2021 Mar;8(1):411-424. doi: 10.1007/s40744-021-00279-y. Epub 2021 Feb 18.

Study record dates

Study Major Dates

• Study Start (Actual): February 15, 2018
• Primary Completion (Anticipated): December 20, 2025
• Study Completion (Anticipated): December 20, 2028

Study Registration Dates

• First Submitted: January 19, 2018
• First Submitted That Met QC Criteria: February 1, 2018
• First Posted (Actual): February 8, 2018

Study Record Updates

• Last Update Posted (Actual): April 18, 2022
• Last Update Submitted That Met QC Criteria: April 11, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Keywords: Flare; Axial Spondyloarthritis; Anti-Inflammatory Drugs
• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Disease Attributes; Joint Diseases; Musculoskeletal Diseases; Arthritis; Spinal Diseases; Bone Diseases; Bone Diseases, Infectious; Recurrence; Spondylitis; Spondylarthritis; Physiological Effects of Drugs; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Anti-Inflammatory Agents, Non-Steroidal
• Other Study ID Numbers: 20180101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes